- Home
- RERE vs MREO Comparison
RERE vs MREO Comparison
Compare RERE & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RERE
- MREO
- Stock Information
- Founded
- RERE 2011
- MREO 2015
- Country
- RERE China
- MREO United Kingdom
- Employees
- RERE N/A
- MREO N/A
- Industry
- RERE Other Specialty Stores
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- RERE Consumer Discretionary
- MREO Health Care
- Exchange
- RERE Nasdaq
- MREO Nasdaq
- Market Cap
- RERE 444.1M
- MREO 438.8M
- IPO Year
- RERE 2021
- MREO N/A
- Fundamental
- Price
- RERE $3.56
- MREO $1.66
- Analyst Decision
- RERE
- MREO Strong Buy
- Analyst Count
- RERE 0
- MREO 5
- Target Price
- RERE N/A
- MREO $7.20
- AVG Volume (30 Days)
- RERE 2.5M
- MREO 3.6M
- Earning Date
- RERE 08-19-2025
- MREO 08-12-2025
- Dividend Yield
- RERE N/A
- MREO N/A
- EPS Growth
- RERE N/A
- MREO N/A
- EPS
- RERE 0.07
- MREO N/A
- Revenue
- RERE $2,388,301,386.00
- MREO N/A
- Revenue This Year
- RERE $27.37
- MREO N/A
- Revenue Next Year
- RERE $24.06
- MREO $52.34
- P/E Ratio
- RERE $49.00
- MREO N/A
- Revenue Growth
- RERE 26.09
- MREO N/A
- 52 Week Low
- RERE $2.00
- MREO $1.58
- 52 Week High
- RERE $4.35
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- RERE 59.53
- MREO 29.70
- Support Level
- RERE $3.49
- MREO $2.77
- Resistance Level
- RERE $4.35
- MREO $3.05
- Average True Range (ATR)
- RERE 0.29
- MREO 0.18
- MACD
- RERE 0.03
- MREO -0.06
- Stochastic Oscillator
- RERE 47.52
- MREO 9.76
About RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).